Organization (Nonprofit)
Radiation Therapy Oncology Group
ClinicalTrials.gov lists Radiation Therapy Oncology Group as lead sponsor of 155 trials. It has 107 active development programs and 67 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Radiation Therapy Oncology Group: 155 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (84)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Head and Neck Neoplasms | 37 |
| Lung Neoplasms | 36 |
| Prostatic Neoplasms | 36 |
| Carcinoma, Non-Small-Cell Lung | 30 |
| Carcinoma, Squamous Cell | 30 |
Showing 5 of 84 disease areas.
Trials by start year as sponsor or collaborator (31)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2023 | 1 |
| 2021 | 1 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 6 |
Showing 10 of 31 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (107)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| CISPLATIN | Head and Neck Neoplasms | Phase 3 | 24 |
| Radiation Therapy | Prostatic Neoplasms | Phase 3 | 12 |
| CISPLATIN | Lung Neoplasms | Phase 3 | 9 |
| Bicalutamide | Prostatic Neoplasms | Phase 3 | 8 |
| ETOPOSIDE | Lung Neoplasms | Phase 3 | 7 |
Showing 5 of 107 active programs.
Approved assets (67)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| CISPLATIN | 43 |
| (nab)-paclitaxel | 22 |
| FLUOROURACIL | 15 |
| FILGRASTIM | 10 |
| Flutamide | 9 |
Showing 5 of 67 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 27% hit target (n=11) | 50% on time (n=18) |
Journals published in (73)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| International journal of radiation oncology, biology, physics | 109 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 73 |
| Cancer | 16 |
| JAMA oncology | 16 |
| Neuro-oncology | 10 |
Showing 5 of 73 journals.
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 6 |
| Cancer and Leukemia Group B | Co sponsors trial with | 3 |
| European Organisation for Research and Treatment of Cancer - EORTC | Co sponsors trial with | 2 |
| Varian Medical Systems (United States) | Co sponsors trial with | 1 |
| King Faisal Specialist Hospital & Research Center | Co sponsors trial with | 1 |
Latest dated events (195)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-10-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-11-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2021-06-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2019-04-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 195 events.
Biomarker capability evidence (273)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGER | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 273 evidence rows.
Biomarkers this organization publishes on (3)
Shown in this order: most publications first.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.